

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-22. (Cancelled)

23. (Currently amended) A method of inhibiting binding of IL-13 to the IL-13 receptor in a mammalian subject, said method comprising administering a polypeptide encoded by a polynucleotide that hybridizes ~~at high stringency~~ under conditions comprising hybridization at 65<sup>0</sup>C in 0.1x SSC to the complement of the portion of SEQ ID NO:3 that encodes about from about amino acid 26 to about amino acid 341 of SEQ ID NO:4, wherein said polypeptide is administered in an amount sufficient to inhibit binding of IL-13 to the IL-13 receptor.

24-27. (Cancelled)

28. (Currently amended) A method of treating an IL-13-related condition in a mammalian subject, said method comprising administering a therapeutically effective amount of a polypeptide encoded by a polynucleotide that hybridizes ~~at high stringency~~ under conditions comprising hybridization at 65<sup>0</sup>C in 0.1x SSC to the complement of the portion of SEQ ID NO:3 that encodes about from about amino acid 26 to about amino acid 341 of SEQ ID NO:4, and wherein said IL-13 related condition is selected from the group consisting of an allergic condition, atopy, and asthma.

29-47. (Cancelled)

48. (Previously presented) The method of claim 23, wherein said polypeptide comprises from about amino acid 26 to about amino acid 341 of SEQ ID NO:4.

49. (Previously presented) The method of claim 23, wherein said polypeptide is part of a fusion protein.

50. (Previously presented) The method of claim 49, wherein said fusion protein comprises an antibody fragment.

51. (Previously presented) The method of claim 50, wherein said antibody fragment includes an Fc fragment.

52. (Previously presented) The method of claim 48, wherein said polypeptide is part of a fusion protein.

53. (Previously presented) The method of claim 52, wherein said fusion protein comprises an antibody fragment.

54. (Cancelled)

55. (Previously presented) The method of claim 48, wherein said polypeptide comprises amino acids 26-341 of SEQ ID NO:4.

56. (Previously presented) The method of claim 28, wherein said IL-13 related condition is an allergic condition.

57. (Previously presented) The method of claim 28, wherein said IL-13 related condition is asthma.

58. (Previously presented) The method of claim 28, wherein said IL-13 related condition is atopy.

59. (Previously presented) The method of claim 28, wherein said polypeptide comprises from about amino acid 26 to about amino acid 341 of SEQ ID NO:4.

60. (Previously presented) The method of claim 28, wherein said polypeptide is part of a fusion protein.

61. (Previously presented) The method of claim 60, wherein said fusion protein comprises an antibody fragment.

62. (Previously presented) The method of claim 59, wherein said polypeptide is part of a fusion protein.

63. (Cancelled)

64. (Previously presented) The method of claim 57, wherein said polypeptide comprises from about amino acid 26 to about amino acid 341 of SEQ ID NO:4.

65. (Previously presented) The method of claim 64, wherein said polypeptide is part of a fusion protein.

66. (Previously presented) The method of claim 65, wherein said fusion protein comprises an antibody fragment.

**Applicants:.** Collins et al.  
**U.S.S.N.** 09/868,123

67. (Previously presented) The method of claim 66, wherein said antibody fragment includes an Fc fragment.